Coherus Biosciences (CHRS) Stock Statistics & Valuation Metrics

Coherus Biosciences has a market cap or net worth of $242.17M. The enterprise value is $136.21M.

Coherus Biosciences has 154,249,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Coherus Biosciences’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -151.77%.

The current PE Ratio of Coherus Biosciences is ―. Coherus Biosciences’s PEG ratio is 0.00148.

In the last 12 months, Coherus Biosciences had revenue of 42.17M and earned -170.29M in profits. Earnings per share was -1.45.

In the last 12 months, operating cash flow was -170.57M and capital expenditures 0.00, giving a free cash flow of -170.57M billion.

Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Coherus Biosciences upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Coherus Biosciences as a current ratio of 1.46, with Debt / Equity ratio of 69.16%

In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.

Coherus Biosciences EV to EBITDA ratio is -0.70, with an EV/FCF ratio of -0.88.

Coherus Biosciences has $167.05M in cash and marketable securities with $54.37M in debt, giving a net cash position of $112.68M billion.

Gross margin is 60.04%, with operating margin of -425.72%, and net profit margin of -403.80%.

The average price target for Coherus Biosciences is $8.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy